[1]俄洛吉*,张长存,李玉琴.甲基多巴联合丹参注射液对妊娠期高血压疾病患者血清相关因子水平变化及母婴结局的影响[J].中国计划生育和妇产科,2018,(9):89-92,94.
　E Luo-ji*,ZHANG Chang-cun,LI Yu-qin.Effect of methyldopa combined with Danshen injection on changes of serum related factors and maternal and infant outcomes in patients with hypertensive disorder complicating pregnancy[J].Chinese Journal of Family Planning & Gynecotokology,2018,(9):89-92,94.
点击复制

甲基多巴联合丹参注射液对妊娠期高血压疾病患者血清相关因子水平变化及母婴结局的影响
分享到：

《中国计划生育和妇产科》[ISSN:1674-4020/CN:51-1708/R]

卷:
期数:
2018年9期
页码:
89-92,94
栏目:
论著与临床
出版日期:
2018-09-25

文章信息/Info

Title:
Effect of methyldopa combined with Danshen injection on changes of serum related factors and maternal and infant outcomes in patients with hypertensive disorder complicating pregnancy
作者:
俄洛吉*; 张长存; 李玉琴
青海省人民医院产科
Author(s):
E Luo-ji*; ZHANG Chang-cun; LI Yu-qin
Obstetrician's Office，Qinghai Provincial People's Hospital，Xining Qinghai 810000，P.R.China
关键词:
妊娠期高血压疾病; 甲基多巴; 丹参注射液; PGE2; Ghrelin; ET-1; 母婴结局
Keywords:
hypertensive disorder complicating pregnancy; methyldopa; Danshen injection; PGE2; Ghrelin; ET-1; maternal and neonatal outcome
分类号:
R 71424
摘要:
目的探讨甲基多巴联合丹参注射液对妊娠期高血压疾病患者血清相关因子水平变化及母婴结局的影响。方法选取2014年11月至2017年7月青海省人民医院收治的98例妊娠期高血压疾病患者，根据随机数字表法分为观察组和对照组，每组49例。两组入院后均给予常规治疗及硫酸镁注射液解痉、镇静，在此基础上，对照组给予甲基多巴治疗，观察组给予甲基多巴+丹参注射液治疗。对比两组治疗前后血压［收缩压（systolic blood pressure，SBP）、舒张压（diastolic blood pressure，DBP）］控制情况、血清相关因子［前列腺素E2（prostaglandin E2，PGE2）、胃饥饿素（ghrelin）、内皮素-1（endothelin 1，ET-1）］水平、分娩方式及不良妊娠结局发生率，统计两组治疗期间不良反应发生率。结果① 血压控制：两组SBP、DBP水平治疗前比较差异无统计学意义（P＞005），治疗后均明显改善（P＜005），且观察组SBP、DBP水平低于对照组（P＜005）。② 血清相关因子：两组血清PGE2、Ghrelin、ET-1水平治疗前比较差异无统计学意义（P＞005），治疗后均明显改善（P＜005），且观察组血清ET-1水平低于对照组，PGE2、Ghrelin水平高于对照组（P＜005）。③ 分娩方式及母婴结局：观察组阴道分娩率（6327 %）高于对照组（4286 %）（P＜005）；早产、胎儿窘迫发生率（1633 %、1020 %）均低于对照组（3469 %、2653%）（P＜005）；两组产后出血、新生儿窒息发生率比较差异无统计学意义（P＞005）。④ 安全性：两组不良反应发生率比较差异无统计学意义（P＞005）。结论甲基多巴联合丹参注射液治疗妊娠期高血压疾病，血压控制效果较佳，可有效改善患者血清PGE2、Ghrelin、ET-1水平，降低不良妊娠结局发生率，且具有一定安全性。
Abstract:
ObjectiveTo investigate the effect of methyldopa combined with Danshen injection on changes of serum related factor levels and maternal and infant outcomes in patients with hypertensive disorder complicating pregnancy（HDCP）. MethodsA total of 98 patients with HDCP from November 2014 to July 2017 in Qinghai Provincial People's Hospital were selected and divided into the observation group and the control group according to random number table, with 49 cases in each group. Both groups were given routine treatment and magnesium sulfate injection for spasmolysis and sedation after admission. On this basis，the control group was given methyldopa treatment, and the observation group was given Danshen injection and methyldopa. The blood pressure control condition［systolic blood pressure (SBP), diastolic blood pressure (DBP)］, serum related factors levels ［prostaglandin E2 (PGE2), ghrelin (Ghrelin), endothelin -1 (ET-1)］, mode of delivery and incidence of adverse pregnancy outcomes were compared between the two groups before and after treatment. The incidence of adverse reactions in the two groups during treatment was counted. Results ① Blood pressure control : there were no significant differences in the levels of SBP and DBP between the two groups before treatment（P＞005）. After treatment, both group were improved（P＜005）, and the levels of SBP and DBP in the observation group were lower than those in the control group（P＜005）. ② Serum related factors: there were no significant differences in serum PGE2, Ghrelin and ET-1 levels between the two groups before treatment（P＞005）. After treatment, all of them in the two groups were improved（P＜005）, and the level of serum ET-1 in the observation group was lower than that in the control group, and the levels of PGE2 and Ghrelin were higher than those of the control group（P＜005）. ③ The mode of delivery and maternal fetal outcomes: the vaginal delivery rate of the observation group (6327 %） was higher than that in the control group (4286 %)（P＜005）; the incidence of preterm birth and fetal distress （1633 %, 1020 %）were lower than those in the control group ( 3469 % , 2653 %)（P＜005）. There were no significant differences in the incidence of postpartum hemorrhage and neonatal asphyxia between the two groups（P＞005）.④ Safety: there were no significant difference in the incidence of adverse reactions between two groups（P＞005）. ConclusionMethyldopa combined with Danshen injection in the treatment of patients with HDCP, has good blood pressure control effect. It can effectively improve the serum levels of PGE2, Ghrelin and ET-1, reduce the incidence of adverse pregnancy outcomes, and has certain safety.

参考文献/References:

［1］邵博一，娄明，蒋春英．硝苯地平缓释片和硫酸镁注射液联合酚妥拉明治疗妊娠期高血压综合征的临床疗效及对妊娠结局的影响 ［J］．实用心脑肺血管病杂志，2017，25（5）：102-104． ［2］Veerbeek JH, Hermes W, Breimer AY, et al. Cardiovascular disease risk factors after early-onset preeclampsia, late-onset preeclampsia, and pregnancy-induced hypertension ［J］. Hypertension, 2015, 65(3): 600-606. ［3］路艳辉，韩连菊，张蕾，等．低分子肝素钙联合丹参注射液对妊高征患者血清前列腺素E2水平的影响 ［J］．河北医药，2016，38（11）：1661-1663． ［4］蔡珏瑾，蔡婷婷．妊娠期高血压与正常妊娠孕妇凝血功能及血小板状态的差异研究 ［J］．实用心脑肺血管病杂志，2016，24（8）：123-124． ［5］Kim JS, Choi YJ. The relationship between preeclampsia,pregnancy-induced hypertension and maternal risk of breast cancer: a meta-analysis ［J］. Annals of Oncology, 2012, 23(9): 454. ［6］王益群．妊娠期高血压疾病相关影响因素及对妊娠结局影响的研究 ［J］．中华全科医学，2015，13（4）：602-604． ［7］Tuuri AL, Jauhiainen MS, Ehnholm CP, et al. Elevated serum angiopoietin-like protein 6 in women with subsequent pregnancy-induced hypertension: a preliminary study ［J］. Hypertension in Pregnancy, 2013, 32(3): 203-213. ［8］邱丹花．复方丹参注射液对妊高症患者GHS-RmRNA及Ghrelin表达的影响 ［J］．中国医药科学，2016，6（24）：38-40． ［9］杨孜，张为远．妊娠期高血压疾病诊治指南(2015)解读［J］．中国实用妇科与产科杂志，2015，31（10）：886-893． ［10］李婕，蒋卫民，李海涛，等．中医药治疗妊娠期高血压疾病的研究进展 ［J］．辽宁中医杂志，2016，43（5）：1110-1112． ［11］冯永亮，彭婷婷，王芳，等．妊娠期高血压疾病对出生结局的影响及相关因素 ［J］．中华疾病控制杂志，2014，18（2）：131-134． ［12］廖运先，王晨虹．妊娠期高血压疾病硫酸镁及降压药的应用 ［J］．中国计划生育和妇产科，2016，8（5）：6-8． ［13］高红．妊娠和哺乳期降压药物选择 ［J］．临床药物治疗杂志，2014，12（6）：49-54． ［14］郭欣，刘清，方芳，等．妊娠期高血压患者血脂和凝血指标变化及与围产期结局的关系 ［J］．中国慢性病预防与控制，2017，25（3）：229-231． ［15］Koenig JM, Chegini N. Enhanced expression of Fas-associated proteins in decidual and trophoblastic tissues in pregnancy-induced hypertension ［J］. American Journal of Reproductive Immunology, 2000, 44(6): 347-349. ［16］马丙祥，董宠凯．丹参的药理作用研究新进展 ［J］．中国药房，2014，25（7）：663-665． ［17］王晋萍，李占辉．丹参注射液和硫酸镁联合治疗对妊娠期高血压疾病患者分娩结局及血清脂联素表达的影响 ［J］．新乡医学院学报，2016，33（9）：764-766． ［18］宋娟利．复方丹参注射液联合硫酸镁治疗妊娠期高血压疾病及对患者微炎症状态、肾功能的影响 ［J］．陕西中医，2016，37（4）：406-407． ［19］杨永碧．血清脂联素在妊娠期高血压疾病中的变化及其与胰岛素抵抗的关系 ［J］．实用临床医药杂志，2014，18（3）：124-126． ［20］闫东芝，杨海澜．子痫前期炎症免疫过度激活的研究进展 ［J］．中国优生与遗传杂志，2016，24（8）：136-138． ［21］王晶，东星，尚丽新，等．妊娠期高血压疾病患者胎盘中Ghrelin水平变化及意义 ［J］．中国优生与遗传杂志，2014，22（9）：89-90．

相似文献/References:

[1]黄辉秀,谭毅.妊娠期高血压疾病预测和预防的研究现状[J].中国计划生育和妇产科,2009,(05):0.
　HUANG Hui-xiu,TAN Yi MCH Hospital of Fangcheng urban district,Fangchenggang city Guangxi automous region 80,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2009,(9):0.
[2]张珺,仲红丽.妊娠期高血压疾病监测系统预测及早期干预520例临床分析[J].中国计划生育和妇产科,2009,(06):0.
[3]肖兵,高岩,熊庆,等.妊娠期高血压疾病的流行病学研究进展[J].中国计划生育和妇产科,2010,(01):0.
[4]何怡,赵可文,唐莉,等.卡孕栓防治妊娠期高血压疾病产后出血的疗效观察[J].中国计划生育和妇产科,2010,(02):0.
　HE Yi,ZHAO Ke-wen,TANG LiMCH hospital of Dongguan city,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2010,(9):0.
[5]庞春蓉,傅晓冬.肾上腺髓质素与妊娠期高血压疾病[J].中国计划生育和妇产科,2010,(02):0.
[6]陈倩,段成城,傅晓冬,等.血清T辅助细胞比率与妊娠期高血压疾病的关系和意义[J].中国计划生育和妇产科,2010,(03):0.
　CHEN Qian,DUAN Cheng-cheng,FU Xiao-dong..[J].Chinese Journal of Family Planning & Gynecotokology,2010,(9):0.
[7]陈茜松,刘丽俊,季淑英,等.妊娠期高血压疾病患者血清抵抗素水平的变化及其临床意义[J].中国计划生育和妇产科,2011,(03):0.
　CHEN Qian-song,LIU Li-jun,JI Shu-ying.[J].Chinese Journal of Family Planning & Gynecotokology,2011,(9):0.
[8]侯卫萍,程兰,黄立,等.血清胱抑素C在妊娠期高血压疾病中的应用[J].中国计划生育和妇产科,2011,(06):0.
　HOU Wei-ping,CHENG Lan,HUANG Li.[J].Chinese Journal of Family Planning & Gynecotokology,2011,(9):0.
[9]刘圣英,杨建恩.孕期补钙预防高危孕妇妊娠期高血压疾病的临床观察[J].中国计划生育和妇产科,2012,(03):0.
　LIU Sheng-ying,YANG Jian-en.[J].Chinese Journal of Family Planning & Gynecotokology,2012,(9):0.
[10]金爽,尹春艳.IGF-Ⅰ、IGF-Ⅱ、IGFBP-1与妊娠期高血压疾病的相关性研究[J].中国计划生育和妇产科,2012,(05):0.
　JIN Shuang,YIN Chun-yan University of South China Teaching Hospital,the Second Peoples Hospital in Guangdong Province,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2012,(9):0.

更新日期/Last Update: 2018-09-25